OCI Valuation
Is OCI undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of OCI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: OCI (€11.32) is trading above our estimate of fair value (€10.3)
Significantly Below Fair Value: OCI is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for OCI?
Key metric: As OCI is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is OCI's PS Ratio? | |
|---|---|
| PS Ratio | 1.3x |
| Sales | US$1.95b |
| Market Cap | US$2.48b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.9x |
| Enterprise Value/EBITDA | -78.9x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does OCI's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1x | ||
CRBN Corbion | 0.9x | -0.2% | €1.3b |
APAM Aperam | 0.3x | 6.1% | €2.0b |
AKZA Akzo Nobel | 0.9x | 3.0% | €9.5b |
600486 Jiangsu Yangnong Chemical | 2.1x | 18.0% | CN¥21.5b |
OCI OCI | 1.3x | 3.6% | €2.4b |
Price-To-Sales vs Peers: OCI is expensive based on its Price-To-Sales Ratio (1.3x) compared to the peer average (1.1x).
Price to Sales Ratio vs Industry
How does OCI's PS Ratio compare vs other companies in the European Chemicals Industry?
| 27 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 27 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: OCI is expensive based on its Price-To-Sales Ratio (1.3x) compared to the European Chemicals industry average (1x).
Price to Sales Ratio vs Fair Ratio
What is OCI's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 1.3x |
| Fair PS Ratio | 0.5x |
Price-To-Sales vs Fair Ratio: OCI is expensive based on its Price-To-Sales Ratio (1.3x) compared to the estimated Fair Price-To-Sales Ratio (0.5x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €11.32 | €18.26 +61.4% | 46.1% | €35.11 | €12.66 | n/a | 9 |
| Nov ’25 | €10.86 | €24.25 +123.4% | 40.9% | €35.31 | €12.30 | n/a | 9 |
| Oct ’25 | €26.12 | €31.75 +21.5% | 6.0% | €34.23 | €29.04 | n/a | 9 |
| Sep ’25 | €28.61 | €31.27 +9.3% | 6.8% | €34.19 | €26.18 | n/a | 12 |
| Aug ’25 | €21.94 | €30.75 +40.2% | 11.5% | €38.20 | €24.13 | n/a | 12 |
| Jul ’25 | €22.63 | €29.86 +31.9% | 14.0% | €37.95 | €21.92 | n/a | 13 |
| Jun ’25 | €25.06 | €29.94 +19.5% | 13.8% | €37.76 | €22.00 | n/a | 13 |
| May ’25 | €25.30 | €30.45 +20.4% | 15.7% | €38.71 | €22.42 | n/a | 12 |
| Apr ’25 | €25.39 | €30.18 +18.9% | 14.9% | €37.88 | €23.29 | n/a | 12 |
| Mar ’25 | €24.25 | €30.60 +26.2% | 14.9% | €38.29 | €23.54 | n/a | 12 |
| Feb ’25 | €26.50 | €28.57 +7.8% | 17.4% | €38.17 | €20.21 | n/a | 12 |
| Jan ’25 | €26.24 | €26.46 +0.8% | 16.4% | €37.57 | €19.90 | n/a | 12 |
| Dec ’24 | €19.58 | €26.82 +37.0% | 16.5% | €37.89 | €20.04 | n/a | 12 |
| Nov ’24 | €21.47 | €30.33 +41.3% | 17.3% | €42.08 | €23.92 | €10.86 | 12 |
| Oct ’24 | €26.39 | €31.16 +18.1% | 15.9% | €42.10 | €24.85 | €26.12 | 12 |
| Sep ’24 | €23.43 | €30.99 +32.3% | 21.5% | €47.21 | €24.19 | €28.61 | 13 |
| Aug ’24 | €24.90 | €29.83 +19.8% | 21.0% | €46.70 | €23.03 | €21.94 | 12 |
| Jul ’24 | €21.97 | €31.92 +45.3% | 21.0% | €46.19 | €25.12 | €22.63 | 12 |
| Jun ’24 | €20.53 | €33.26 +62.0% | 19.9% | €46.79 | €25.45 | €25.06 | 12 |
| May ’24 | €23.89 | €35.03 +46.6% | 17.1% | €45.76 | €24.74 | €25.30 | 11 |
| Apr ’24 | €31.26 | €36.44 +16.6% | 13.9% | €46.74 | €29.80 | €25.39 | 11 |
| Mar ’24 | €31.06 | €36.98 +19.1% | 11.8% | €43.70 | €30.03 | €24.25 | 10 |
| Feb ’24 | €31.26 | €39.37 +25.9% | 8.8% | €45.96 | €32.84 | €26.50 | 10 |
| Jan ’24 | €33.42 | €42.25 +26.4% | 9.3% | €48.13 | €33.26 | €26.24 | 10 |
| Dec ’23 | €39.84 | €43.84 +10.1% | 9.0% | €49.80 | €34.41 | €19.58 | 10 |
| Nov ’23 | €38.68 | €44.83 +15.9% | 9.5% | €52.05 | €35.97 | €21.47 | 10 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
Hydratec Industries
€210.3m
Through its subsidiaries, manufactures and sells industrial systems and plastic components for food, health, and mobility markets in the Netherlands, rest of Europe, Asia, North America, South America, Africa, and Oceania.
HYDRA
€162.00
7D
1.3%
1Y
82.0%
DSM-Firmenich
€28.5b
Provides solutions for nutrition, health, and beauty businesses in the Switzerland, Netherlands, rest of Europe, the Middle East and Africa, North America, Latin America, China, and rest of Asia.
DSFIR
€107.25
7D
4.7%
1Y
21.3%